RBC Capital Markets is cautioning that Brown & Brown, the large insurance broker, may still be in for a rough patch before its revenue growth stabilizes. In a new research note, the bank warns that total revenue could actually turn negative in the fourth quarter of 2026, as year-over-year comparisons become more difficult.
The warning comes even as RBC acknowledges some bright spots, including improving growth in the company's retail segment and a $175 million synergy target tied to its Accession acquisition, which the company expects to achieve by 2028. But the overall tone is cautious: RBC believes the next stretch could look weaker before it looks better.
What's driving the caution?
Brown & Brown is one of the largest independent insurance brokers in the United States, helping businesses and individuals find coverage from a range of insurers. Its revenue comes from commissions and fees, and a portion of that is what are called contingent commissions—bonus-like payments that insurers make to brokers when certain volume or profitability targets are met.
RBC's note points to tough year-end comparisons for those contingent commissions, which could weigh on overall revenue. The bank also expects revenue added through past acquisitions to normalize, meaning it will no longer provide the same boost it once did. Put together, RBC's model shows total revenue potentially dipping below zero in the fourth quarter of 2026, even if organic growth—growth from existing operations—later steadies.
For context, a negative revenue quarter is rare for a company like Brown & Brown, which has historically grown through a mix of acquisitions and organic expansion. But the combination of tougher comparisons and a slowdown in deal-related revenue can create a temporary drag.
Specialty Distribution growth expected to slow
RBC also flagged that the company's Specialty Distribution unit, which provides insurance and risk management services to niche markets, is expected to grow just 1.7% organically in 2027. That's near the low end of management's own guidance range of 1% to 3%, and it follows a recent cut to that unit's fourth-quarter outlook.
That kind of muted growth suggests the broader environment for insurance brokers remains challenging, with pricing pressure and softer demand in some lines of business. It also means Brown & Brown may need to rely more on cost cuts and margin improvements to drive earnings, rather than top-line growth.
What it means for investors
RBC lowered its adjusted earnings per share estimates for Brown & Brown to $4.51 for 2026, $4.78 for 2027, and $5.28 for 2028. But the bank kept its price target at $78 and maintained a “sector perform” rating—essentially saying the stock is fairly valued relative to its peers.
Here's the key nuance: a stock price target is basically earnings times a valuation multiple, known as the price-to-earnings ratio, or P/E. When an analyst cuts earnings forecasts but keeps the same price target, the implied P/E goes up. That means more of the investment case now rests on investors being willing to pay a richer multiple for the stock, rather than just counting on earnings growth to do the heavy lifting.
That can be a tougher setup if macroeconomic conditions remain unfavorable and growth stays muted, as RBC's 1.7% organic-growth view for Specialty Distribution suggests. It also makes execution more central: proof that margins are improving—including progress toward the $175 million Accession synergy target by 2028—can help justify a higher multiple even while revenue growth is still stabilizing.
For everyday investors, this is a reminder that analyst price targets aren't just about earnings forecasts—they also reflect assumptions about how much investors will pay for those earnings. When a target stays flat despite lower estimates, it's a signal that the analyst sees value in the company's longer-term potential, but also that the near-term path may be bumpy.
Brown & Brown has a long track record of successful acquisitions and steady growth, and the Accession deal is expected to add meaningful synergies. But as RBC's note highlights, even well-run companies can hit periods where revenue growth stalls or turns negative. Investors should watch for signs that organic growth is stabilizing, and whether management can deliver on its margin and synergy promises.
For more on how analysts view other companies facing similar growth challenges, see our coverage of Seagate's growth outlook and Corpay's steady growth expectations.
